Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Herpes Simplex Oral Clear all
Completed Phase 1 Interventional Results available

Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis

NCT01971385
View directory record Official record
Conditions
Herpes Labialis
Interventions
Squaric Acid solution, Placebo solution
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

NCT00448227
View directory record Official record
Conditions
Herpes Simplex
Interventions
famciclovir
Drug
Lead sponsor
Novartis
Industry
Eligibility
1 Month to 1 Year
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

NCT01308424
View directory record Official record
Conditions
Oral Herpes Simplex
Interventions
BTL TML HSV, Matching placebo
Drug
Lead sponsor
Beech Tree Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Lexington, Kentucky • Buffalo, New York • Norwich, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

NCT00878072
View directory record Official record
Conditions
Herpes Labialis
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
San Diego, California • Chicago, Illinois • Evansville, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 28, 2026, 9:02 AM EDT
Not listed Phase 3 Interventional

NB-001 Treatment of Recurrent Herpes Labialis

NCT01695187
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001 (0.3%), Placebo
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Sep 28, 2026, 9:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 28, 2026, 9:02 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis

NCT03521479
View directory record Official record
Conditions
Herpes Labialis, HSV
Interventions
Squaric Acid Dibutyl Ester
Drug
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Doral, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 28, 2026, 9:02 AM EDT
Terminated Not applicable Interventional Results available

Botulinum Toxin A for Herpes Labialis

NCT01225341
View directory record Official record
Conditions
Herpes Labialis
Interventions
onabotulinumtoxinA, Bacteriostatic normal saline
Drug · Other
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 28, 2026, 9:02 AM EDT
Not listed Phase 3 Interventional

Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System

NCT00006132
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 28 Days
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Not applicable Interventional

Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster

NCT00006131
View directory record Official record
Conditions
Herpes Zoster, Immunologic Deficiency Syndromes
Interventions
Valacyclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2007 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates

NCT00031460
View directory record Official record
Conditions
Herpes Simplex
Interventions
Acyclovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 28 Days
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

NCT02871492
View directory record Official record
Conditions
Herpes Labialis
Interventions
Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 28, 2026, 9:02 AM EDT
Withdrawn Phase 4 Interventional

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

NCT03626376
View directory record Official record
Conditions
Herpes Simplex Virus Keratitis
Interventions
oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores

NCT05796635
View directory record Official record
Conditions
Cold Sores
Interventions
Herpecin L
Other
Lead sponsor
Focus Consumer Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

NCT00453401
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
28
States / cities
Huntsville, Alabama • Anaheim, California • Westlake Village, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 29, 2008 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

NCT00230867
View directory record Official record
Conditions
Herpes Labialis
Interventions
iontophoretic acyclovir
Device
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
26
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

NCT00297011
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir+clobetasol gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

NCT05098938
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 3 Interventional

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

NCT00209352
View directory record Official record
Conditions
VZV Infection After Bone Marrow Transplantation
Interventions
Acyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2 Interventional

The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU

NCT00000654
View directory record Official record
Conditions
Herpes Simplex, HIV Infections, Hepatitis B
Interventions
Fialuridine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores

NCT03192306
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
Merlin, Ethanol
Drug
Lead sponsor
Topical Remedy
Industry
Eligibility
18 Years to 75 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 1 Interventional

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

NCT00297206
View directory record Official record
Conditions
Herpes Simplex
Interventions
Valaciclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Month to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 28, 2026, 9:02 AM EDT
Completed Phase 2 Interventional

Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

NCT00469300
View directory record Official record
Conditions
Herpes Labialis
Interventions
Iontophoretic delivery of acyclovir
Drug
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Rosa, California • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2008 · Synced Sep 28, 2026, 9:02 AM EDT